I have posted this item as a "response" also. I guessed it may be of sufficient interest to post as a separate item. Apologies if it is a repeat.
RB
http://www.docguide.com/news/content...2570D9005F0ADD
ABSTRACT
SAN ANTONIO, TX -- December 16, 2005 -- The Breast Cancer International Research Group (BCIRG) and the sanofi-aventis Group today announced the results from the first interim efficacy and updated safety analyses from the BCIRG 006 phase 3 breast cancer study, which show that Herceptin(R) combined with Taxotere(R)-based regimens significantly improved disease free survival for women with early HER2-positive breast cancer.
This data was presented at the 28th annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, United States.
Cardiac and global safety data together with the interim efficacy analysis based on 322 events were reviewed by an Independent Data Monitoring Committee (IDMC). The relative reduction in the risk of relapse were: 51% [95% CI: 35%-63%], P <.001 and 39% [95% CI: 21%-53%], p-value of <0.001 for the AC-TH and TCH arms, respectively, when compared to the control arm of AC- T. There was no statistically significant difference between the 2 Herceptin(R) -containing experimental arms. Overall survival data is not yet mature.
Linear Mode
